Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.

Eqbal, Ali; Hilley, Patrick; Choy, Matthew; Srinivasan, Ashish; de Cruz, Peter

Eqbal, Ali; Hilley, Patrick; Choy, Matthew; Srinivasan, Ashish; de Cruz, Peter.

Afiliação

Eqbal A; Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.
Hilley P; Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.
Choy M; Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.
Srinivasan A; Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.
de Cruz P; Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.

Intern Med J ; 53(8): 1497-1500, 2023 08.

Article em En | MEDLINE | ID: mdl-37599224

Assuntos

Colite Ulcerativa; Humanos; Colite Ulcerativa/tratamento farmacológico; Infliximab/uso terapêutico; Estudos Prospectivos; Austrália

Palavras-chave

acute severe colitis; sequential therapy; tofacitinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google